Lantern Pharma Inc. filed a Current Report on Form 8-K on September 23, 2026, disclosing a press release describing topics to be covered during a live webinar hosted by the company on September 23, 2026, focused on its Open-Medicine AI platform for drug development.

Key Highlights

  • Event date: Lantern Pharma hosted a live webinar on September 23, 2026.
  • Subject matter: The webinar was convened to discuss Open-Medicine AI, described in the filing as "a multi-agentic AI platform for drug development."
  • Disclosure vehicle: A press release dated September 23, 2026, was furnished as Exhibit 99.1 and incorporated by reference into the filing.
  • Regulation FD: The disclosure was made under Item 7.01, Regulation FD Disclosure.
  • Signing officer: The report was signed by David R. Margrave, Chief Financial Officer.

Lantern Pharma Discloses AI Drug Development Webinar Under Regulation FD

According to the filing, Lantern Pharma Inc. (NASDAQ:LTRN), a Delaware corporation headquartered at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201, submitted a Current Report on Form 8-K to satisfy its Regulation FD disclosure obligations. The report states that on September 23, 2026, the company issued a press release describing topics to be covered during a live webinar it hosted on the same date.

The filing identifies the webinar's subject as Open-Medicine AI, which it characterizes as "a multi-agentic AI platform for drug development." The press release describing the webinar topics was furnished as Exhibit 99.1. The filing notes that the information in Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not subject to the liabilities of that section unless expressly incorporated by specific reference in a subsequent filing.

No financial statements or financial data were included in this filing. The report was signed on behalf of Lantern Pharma Inc. by David R. Margrave in his capacity as Chief Financial Officer. The filing also includes a Cover Page Interactive Data File formatted as Inline XBRL, listed as Exhibit 104.

What Was Disclosed

Lantern Pharma filed an 8-K on September 23, 2026, under Regulation FD, furnishing a press release as Exhibit 99.1 that describes topics covered during a company-hosted live webinar on its Open-Medicine AI drug development platform.